



Eli Lilly and Company
Elanco Animal Health
Plantin and Moretuslei 1 (3rd floor)
Antwerp - Belgium
Tel: [REDACTED]
e-mail: [REDACTED]

Veterinary Applications
Veterinary Medicines Department
European Medicines Agency
30 Churchill Place
Canary Wharf
London E14 5EU
United Kingdom
Cc: [REDACTED]

Date: 29th of March 2017

Re: Cheristin (EMEA/V/C/004316/0000) – Application for a New Application under Article 3.2 (a) of regulation (EC) N° 726/2004 – Confirmation of withdrawal

Dear [REDACTED]

On behalf of Elanco Europe Ltd. I regret to inform you that the company has decided to withdraw the marketing application for Cheristin and associated ASMF.

Due to the nature of the major objections [REDACTED] we will no longer be able to pursue an application in the EU for the above product. We sincerely apologise for the inconvenience this may cause the Agency and our Rapporteurs. We thank you for your ongoing support and guidance and look forward to future positive interactions.

The applicant would be very grateful for the EMA's kind consideration of this request and please feel free to contact me if you wish to discuss any detail further.

Yours faithfully,

[REDACTED]

[REDACTED]
Regulatory Affairs Manager
Companion Animals Innovation